Carvalho, Lívia MendesFerreira, Francielle CarvalhoGusmão, Miriã RodriguesCosta, Ana Flávia PereiraBrito, Rory Cristiane Fortes deSoares, Rodrigo Dian de Oliveira AguiarReis, Alexandre BarbosaCardoso, Jamille Mirelle de OliveiraCarneiro, Cláudia MartinsRoatt, Bruno Mendes2023-01-262023-01-262021CARVALHO, L. M. et al. Heterologous vaccine therapy associated with half course of Miltefosine promote activation of the proinflammatory response with control of splenic parasitism in a hamster model of visceral leishmaniasis. Current Research in Immunology, v. 2, p. 194-201, 2021. Disponível em: <https://www.sciencedirect.com/science/article/pii/S2590255521000202>. Acesso em: 11 out. 2022.2590-2555http://www.repositorio.ufop.br/jspui/handle/123456789/16056Visceral leishmaniasis (VL) is a serious and neglected disease present worldwide. Chemotherapy using pentavalent antimony (SbV) is the most practical and inexpensive strategy available for the VL treatment today, however, it has high toxicity. Alternatively, other drugs are used as viable leishmanicidal therapeutic options. Miltefosine is the only anti-leishmanial agent administered orally, however, it has been reducing its effectiveness. In this sense, there is no ideal therapy for VL since the drugs currently used trigger severe side effects causing discontinuation of treatment, which carries an imminent risk for the emergence of parasite resistance. With that, other therapeutic strategies are gaining prominence. Among them, immunotherapy and/or immunochemotherapy, which the activation/modulation of the immune system can redirect the host’s immune response to an effective therapeutic result. Therefore, this work was designed to assess an immunochemotherapy protocol composed of half course of Miltefosine associated with LBSap vaccine (Milt+LBSap) using the hamster Mesocricetus auratus as an experimental model for VL treatment. When evaluating the main hematobiochemical, immunological and therapeutic efficacy parameters, it was demonstrated that the treatment with Milt+LBSap showed restoration of hematobiochemical condition and reduced serum levels of IgG-anti-Leishmania compared to animals infected non treated (INT). Beyond that, an increase in the number of CD4+ lymphocytes producers of IFN-γ in relation to INT or to animals treated with miltefosine during 28 days, and TNF-α increased compared to INT were observed. Also, it was found a reduction of IL-10-production in relation to INT, or animals that received LBSap vaccine only, or miltefosine, following by a reduction in the splenic parasitic burden. These results demonstrate that the immunochemotherapy protocol used can stimulate the immune response, inducing an expressive cellular response sufficient to control spleen parasitism, standing out as a promising proposal for the VL treatment.en-USabertoLeishmania infantumImmunochemotherapyArtigo publicado em periodicoThis is an open access article distributed under the terms of the Creative Commons license. Fonte: o PDF do artigo.https://doi.org/10.1016/j.crimmu.2021.10.003